{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:15:54Z","timestamp":1794071754573,"version":"4.8.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N014103\/1"],"award-info":[{"award-number":["MR\/N014103\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N014103\/1"],"award-info":[{"award-number":["MR\/N014103\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2022,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transcriptional deregulation has emerged as a hallmark of several cancer types. In metastatic castration-resistant prostate cancer, a stage in which systemic androgen deprivation therapies fail to show clinical benefit, transcriptional addiction to the androgen receptor is maintained in most patients. This has led to increased efforts to find novel therapies that prevent oncogenic transactivation of the androgen receptor. In this context, a group of druggable protein kinases, known as transcription associated cyclin-dependent kinases (tCDKs), show great potential as therapeutic targets. Despite initial reservations about targeting tCDKs due to their ubiquitous and prerequisite nature, preclinical studies showed that selectively inhibiting such kinases could provide sufficient therapeutic window to exert antitumour effects in the absence of systemic toxicity. As a result, several highly specific inhibitors are currently being trialled in solid tumours, including prostate cancer. This article summarises the roles of tCDKs in regulating gene transcription and highlights rationales for their targeting in prostate cancer. It provides an overview of the most recent developments in this therapeutic area, including the most recent clinical advances, and discusses the utility of tCDK inhibitors in combination with established cancer agents.<\/jats:p>","DOI":"10.1038\/s41388-022-02347-1","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T13:03:34Z","timestamp":1652533414000},"page":"3303-3315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer"],"prefix":"10.1038","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-5165","authenticated-orcid":false,"given":"Theodora A.","family":"Constantin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-4160","authenticated-orcid":false,"given":"Kyle K.","family":"Greenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Varela-Carver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-0552","authenticated-orcid":false,"given":"Charlotte L.","family":"Bevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"key":"2347_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/21541264.2018.1553483","volume":"10","author":"RP Fisher","year":"2019","unstructured":"Fisher RP. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription. 2019;10:47\u201356.","journal-title":"Transcription"},{"key":"2347_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4161\/trns.25146","volume":"4","author":"M Sans\u00f3","year":"2013","unstructured":"Sans\u00f3 M, Fisher RP. Pause, play, repeat. Transcription. 2013;4:146\u201352.","journal-title":"Transcription"},{"key":"2347_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168:629\u201343.","journal-title":"Cell"},{"key":"2347_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/er.2002-0032","volume":"25","author":"CA Heinlein","year":"2004","unstructured":"Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276\u2013308.","journal-title":"Endocr Rev"},{"key":"2347_CR5","doi-asserted-by":"publisher","first-page":"8456","DOI":"10.1021\/cr400071f","volume":"113","author":"D Eick","year":"2013","unstructured":"Eick D, Geyer M. The RNA polymerase II carboxy-terminal domain (CTD) code. Chem Rev. 2013;113:8456\u201390.","journal-title":"Chem Rev"},{"key":"2347_CR6","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1101\/gad.200303.112","volume":"26","author":"JP Hsin","year":"2012","unstructured":"Hsin JP, Manley JL. The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev. 2012;26:2119\u201337.","journal-title":"Genes Dev"},{"key":"2347_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/emboj\/19.1.25","volume":"19","author":"FTF Tsai","year":"2000","unstructured":"Tsai FTF, Sigler PB. Structural basis of preinitiation complex assembly on human Pol II promoters. EMBO J. 2000;19:25\u201336.","journal-title":"EMBO J"},{"key":"2347_CR8","doi-asserted-by":"publisher","first-page":"e44771","DOI":"10.7554\/eLife.44771","volume":"8","author":"BJ Greber","year":"2019","unstructured":"Greber BJ, Toso DB, Fang J, Nogales E. The complete structure of the human TFIIH core complex. Elife. 2019;8:e44771.","journal-title":"Elife"},{"key":"2347_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nrm.2017.115","volume":"19","author":"J Soutourina","year":"2018","unstructured":"Soutourina J. Transcription regulation by the Mediator complex. Nat Rev Mol Cell Biol. 2018;19:262\u201374.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2347_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molcel.2014.03.024","volume":"54","author":"KH Wong","year":"2014","unstructured":"Wong KH, Jin Y, Struhl K. TFIIH phosphorylation of the Pol II CTD stimulates mediator dissociation from the preinitiation complex and promoter escape. Mol Cell. 2014;54:601\u201312.","journal-title":"Mol Cell"},{"key":"2347_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbagrm.2012.08.010","volume":"1829","author":"DS Luse","year":"2013","unstructured":"Luse DS. Promoter clearance by RNA polymerase II. Biochim Biophys Acta. 2013;1829:63\u201368.","journal-title":"Biochim Biophys Acta"},{"key":"2347_CR12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.4161\/rna.21166","volume":"9","author":"S Egloff","year":"2012","unstructured":"Egloff S. Role of Ser7 phosphorylation of the CTD during transcription of snRNA genes. RNA Biol. 2012;9:1033\u20138.","journal-title":"RNA Biol"},{"key":"2347_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2015.06.032","volume":"59","author":"KA Nilson","year":"2015","unstructured":"Nilson KA, Guo J, Turek ME, Brogie JE, Delaney E, Luse DS, et al. THZ1 reveals roles for Cdk7 in co-transcriptional capping and pausing. Mol Cell. 2015;59:576\u201387.","journal-title":"Mol Cell"},{"key":"2347_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2009.09.018","volume":"36","author":"R Perales","year":"2009","unstructured":"Perales R, Bentley D. \u201cCotranscriptionality\u201d: the transcription elongation complex as a nexus for nuclear transactions. Mol Cell. 2009;36:178\u201391.","journal-title":"Mol Cell"},{"key":"2347_CR15","doi-asserted-by":"publisher","first-page":"10009","DOI":"10.1074\/jbc.RA117.001347","volume":"293","author":"U Mbonye","year":"2018","unstructured":"Mbonye U, Wang B, Gokulrangan G, Shi W, Yang S, Karn J. Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem. 2018;293:10009\u201325.","journal-title":"J Biol Chem"},{"key":"2347_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nsmb.2399","volume":"19","author":"S Larochelle","year":"2012","unstructured":"Larochelle S, Amat R, Glover-Cutter K, Sans\u00f3 M, Zhang C, Allen JJ, et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol. 2012;19:1108\u201315.","journal-title":"Nat Struct Mol Biol"},{"key":"2347_CR17","doi-asserted-by":"publisher","first-page":"12335","DOI":"10.1074\/jbc.270.21.12335","volume":"270","author":"NF Marshall","year":"1995","unstructured":"Marshall NF, Price DH. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J Biol Chem. 1995;270:12335\u20138.","journal-title":"J Biol Chem"},{"key":"2347_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.celrep.2017.07.021","volume":"20","author":"CC Ebmeier","year":"2017","unstructured":"Ebmeier CC, Erickson B, Allen BL, Allen MA, Kim H, Fong N, et al. Human TFIIH Kinase CDK7 regulates transcription-associated chromatin modifications. Cell Rep. 2017;20:1173\u201386.","journal-title":"Cell Rep"},{"key":"2347_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.molcel.2007.11.010","volume":"28","author":"RJ Sims","year":"2007","unstructured":"Sims RJ, Millhouse S, Chen CF, Lewis BA, Erdjument-Bromage H, Tempst P, et al. Recognition of Trimethylated Histone H3 Lysine 4 facilitates the recruitment of transcription postinitiation factors and Pre-mRNA splicing. Mol Cell. 2007;28:665\u201376.","journal-title":"Mol Cell"},{"key":"2347_CR20","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1101\/gad.341545.120","volume":"34","author":"JK Rimel","year":"2020","unstructured":"Rimel JK, Poss ZC, Erickson B, Maas ZL, Ebmeier CC, Johnson JL, et al. Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription. Genes Dev. 2020;34:1452\u201373.","journal-title":"Genes Dev"},{"key":"2347_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2008.04.024","volume":"31","author":"F Coin","year":"2008","unstructured":"Coin F, Oksenych V, Mocquet V, Groh S, Blattner C, Egly JM. Nucleotide excision repair driven by the dissociation of CAK from TFIIH. Mol Cell. 2008;31:9\u201320.","journal-title":"Mol Cell"},{"key":"2347_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10745-5","volume":"10","author":"G Kokic","year":"2019","unstructured":"Kokic G, Chernev A, Tegunov D, Dienemann C, Urlaub H, Cramer P. Structural basis of TFIIH activation for nucleotide excision repair. Nat Commun. 2019;10:2885.","journal-title":"Nat Commun"},{"key":"2347_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1101\/gad.14.3.349","volume":"14","author":"SJ Ara\u00fajo","year":"2000","unstructured":"Ara\u00fajo SJ, Tirode F, Coin F, Pospiech H, Syv\u00e4oja JE, Stucki M, et al. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev. 2000;14:349\u201359.","journal-title":"Genes Dev"},{"key":"2347_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/21541264.2017.1344346","volume":"9","author":"S Egloff","year":"2018","unstructured":"Egloff S, Studniarek C, Kiss T. 7SK small nuclear RNA, a multifunctional transcriptional regulatory RNA with gene-specific features. Transcription. 2018;9:95\u2013101.","journal-title":"Transcription"},{"key":"2347_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S1097-2765(03)00388-5","volume":"12","author":"JHN Yik","year":"2003","unstructured":"Yik JHN, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. Inhibition of P-TEFb (CDK9\/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell. 2003;12:971\u201382.","journal-title":"Mol Cell"},{"key":"2347_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","volume":"19","author":"Z Yang","year":"2005","unstructured":"Yang Z, Yik JHN, Chen R, He N, Moon KJ, Ozato K, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19:535\u201345.","journal-title":"Mol Cell"},{"key":"2347_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41586-018-0442-2","volume":"560","author":"SM Vos","year":"2018","unstructured":"Vos SM, Farnung L, Urlaub H, Cramer P. Structure of paused transcription complex Pol II\u2013DSIF\u2013NELF. Nature. 2018;560:601\u20136.","journal-title":"Nature"},{"key":"2347_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.molcel.2005.11.024","volume":"21","author":"T Yamada","year":"2006","unstructured":"Yamada T, Yamaguchi Y, Inukai N, Okamoto S, Mura T, Handa H. P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. Mol Cell. 2006;21:227\u201337.","journal-title":"Mol Cell"},{"key":"2347_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1097-2765(03)00492-1","volume":"13","author":"SH Ahn","year":"2004","unstructured":"Ahn SH, Kim M, Buratowski S. Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3\u2019 end processing. Mol Cell. 2004;13:67\u201376.","journal-title":"Mol Cell"},{"key":"2347_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1126\/science.1206034","volume":"334","author":"JP Hsin","year":"2011","unstructured":"Hsin JP, Sheth A, Manley JL. RNAP II CTD phosphorylated on threonine-4 is required for histone mRNA 3\u2032 end processing. Science. 2011;334:683\u20136.","journal-title":"Science"},{"key":"2347_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1101\/gad.269589.115","volume":"30","author":"M Sans\u00f3","year":"2016","unstructured":"Sans\u00f3 M, Levin RS, Lipp JJ, Wang VYF, Greifenberg AK, Quezada EM, et al. P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for Cdk9 substrates. Genes Dev. 2016;30:117\u201331.","journal-title":"Genes Dev"},{"key":"2347_CR32","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/embor.2009.108","volume":"10","author":"J Pirngruber","year":"2009","unstructured":"Pirngruber J, Shchebet A, Schreiber L, Shema E, Minsky N, Chapman RD, et al. CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3\u2032-end processing. EMBO Rep. 2009;10:894\u2013900.","journal-title":"EMBO Rep"},{"key":"2347_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nsmb.3000","volume":"22","author":"C Laitem","year":"2015","unstructured":"Laitem C, Zaborowska J, Isa NF, Kufs J, Dienstbier M, Murphy S. CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II-transcribed genes. Nat Struct Mol Biol. 2015;22:396\u2013403.","journal-title":"Nat Struct Mol Biol"},{"key":"2347_CR34","doi-asserted-by":"publisher","first-page":"eabd4484","DOI":"10.1126\/sciadv.abd4484","volume":"7","author":"YC Li","year":"2021","unstructured":"Li YC, Chao TC, Kim HJ, Cholko T, Chen SF, Li G, et al. Structure and noncanonical Cdk8 activation mechanism within an Argonaute-containing Mediator kinase module. Sci Adv. 2021;7:eabd4484.","journal-title":"Sci Adv"},{"key":"2347_CR35","doi-asserted-by":"publisher","first-page":"004","DOI":"10.4172\/jpb.S2-004","volume":"01","author":"DL Daniels","year":"2013","unstructured":"Daniels DL, Ford M, Schwinn MK, Benink H, Galbraith MD, Amunugama R, et al. Mutual exclusivity of MED12\/MED12L, MED13\/13L, and CDK8\/19 paralogs revealed within the CDK-mediator kinase module. J Proteom Bioinform. 2013;01:004.","journal-title":"J Proteom Bioinform"},{"key":"2347_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41588-020-0635-0","volume":"52","author":"MG Jaeger","year":"2020","unstructured":"Jaeger MG, Schwalb B, Mackowiak SD, Velychko T, Hanzl A, Imrichova H, et al. Selective Mediator-dependence of cell type-specifying transcription. Nat Genet. 2020;52:719\u201327.","journal-title":"Nat Genet"},{"key":"2347_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature14904","volume":"526","author":"HE Pelish","year":"2015","unstructured":"Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, et al. Mediator Kinase inhibition further activates super-enhancer associated genes in AML. Nature. 2015;526:273\u20136.","journal-title":"Nature"},{"key":"2347_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.celrep.2016.03.030","volume":"15","author":"ZC Poss","year":"2016","unstructured":"Poss ZC, Ebmeier CC, Odell AT, Tangpeerachaikul A, Lee T, Pelish HE, et al. Identification of Mediator kinase substrates in human cells using cortistatin A and quantitative phosphoproteomics. Cell Rep. 2016;15:436\u201350.","journal-title":"Cell Rep"},{"key":"2347_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/21541264.2018.1535211","volume":"10","author":"AL Greenleaf","year":"2019","unstructured":"Greenleaf AL. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium. Transcription. 2019;10:91\u2013110.","journal-title":"Transcription"},{"key":"2347_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09703-y","volume":"10","author":"M Krajewska","year":"2019","unstructured":"Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019;10:1757.","journal-title":"Nat Commun"},{"key":"2347_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","volume":"564","author":"SJ Dubbury","year":"2018","unstructured":"Dubbury SJ, Boutz PL, Sharp PA. Cdk12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature. 2018;564:141\u20135.","journal-title":"Nature"},{"key":"2347_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41589-021-00765-y","volume":"17","author":"B Jiang","year":"2021","unstructured":"Jiang B, Gao Y, Che J, Lu W, Kaltheuner IH, Dries R, et al. Discovery and resistance mechanism of a selective CDK12 degrader. Nat Chem Biol. 2021;17:675\u201383.","journal-title":"Nat Chem Biol"},{"key":"2347_CR43","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1093\/nar\/gkx187","volume":"45","author":"JF Tien","year":"2017","unstructured":"Tien JF, Mazloomian A, Cheng SWG, Hughes CS, Chow CCT, Canapi LT, et al. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res. 2017;45:6698\u2013716.","journal-title":"Nucleic Acids Res"},{"key":"2347_CR44","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1128\/MCB.01426-14","volume":"35","author":"K Liang","year":"2015","unstructured":"Liang K, Gao X, Gilmore JM, Florens L, Washburn MP, Smith E, et al. Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol Cell Biol. 2015;35:928\u201338.","journal-title":"Mol Cell Biol"},{"key":"2347_CR45","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/sj.onc.1204295","volume":"20","author":"M Kasten","year":"2001","unstructured":"Kasten M, Giordano A. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene. 2001;20:1832\u20138.","journal-title":"Oncogene"},{"key":"2347_CR46","doi-asserted-by":"publisher","first-page":"19525","DOI":"10.1073\/pnas.1306814110","volume":"110","author":"VJ Guen","year":"2013","unstructured":"Guen VJ, Gamble C, Flajolet M, Unger S, Thollet A, Ferandin Y, et al. CDK10\/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc Natl Acad Sci USA. 2013;110:19525\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2347_CR47","doi-asserted-by":"publisher","first-page":"7721","DOI":"10.1074\/jbc.M708188200","volume":"283","author":"P Loyer","year":"2008","unstructured":"Loyer P, Trembley JH, Grenet JA, Busson A, Corlu A, Zhao W, et al. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J Biol Chem. 2008;283:7721\u201332.","journal-title":"J Biol Chem"},{"key":"2347_CR48","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41594-020-0406-8","volume":"27","author":"P Gajdu\u0161kov\u00e1","year":"2020","unstructured":"Gajdu\u0161kov\u00e1 P, Ruiz de los Mozos I, R\u00e1jeck\u00fd M, Hluch\u00fd M, Ule J, Blazek D. CDK11 is required for transcription of replication-dependent histone genes. Nat Struct Mol Biol. 2020;27:500\u201310.","journal-title":"Nat Struct Mol Biol"},{"key":"2347_CR49","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644\u20138.","journal-title":"Science"},{"key":"2347_CR50","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/sj.bjc.6604054","volume":"97","author":"RK Nam","year":"2007","unstructured":"Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer. 2007;97:1690\u20135.","journal-title":"Br J Cancer"},{"key":"2347_CR51","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/ng.3419","volume":"47","author":"MM Pomerantz","year":"2015","unstructured":"Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47:1346\u201351.","journal-title":"Nat Genet"},{"key":"2347_CR52","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.ejca.2014.04.004","volume":"50","author":"TA West","year":"2014","unstructured":"West TA, Kiely BE, Stockler MR. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. Eur J Cancer. 2014;50:1916\u201324.","journal-title":"Eur J Cancer"},{"key":"2347_CR53","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/emboj.2010.337","volume":"30","author":"P Chymkowitch","year":"2011","unstructured":"Chymkowitch P, Le May N, Charneau P, Compe E, Egly JM. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin\/proteasome process. EMBO J. 2011;30:468\u201379.","journal-title":"EMBO J"},{"key":"2347_CR54","doi-asserted-by":"publisher","first-page":"20989","DOI":"10.1074\/jbc.M802392200","volume":"283","author":"LA Ponguta","year":"2008","unstructured":"Ponguta LA, Gregory CW, French FS, Wilson EM. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem. 2008;283:20989\u20131001.","journal-title":"J Biol Chem"},{"key":"2347_CR55","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1158\/2159-8290.CD-19-0189","volume":"9","author":"R Ur Rasool","year":"2019","unstructured":"Ur Rasool R, Natesan R, Deng Q, Aras S, Lal P, Effron SS, et al. CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation. Cancer Discov. 2019;9:1538\u201355.","journal-title":"Cancer Discov"},{"key":"2347_CR56","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1210\/me.2010-0238","volume":"24","author":"V Gordon","year":"2010","unstructured":"Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, et al. CDK9 regulates AR promoter selectivity and cell growth through Serine 81 phosphorylation. Mol Endocrinol. 2010;24:2267\u201380.","journal-title":"Mol Endocrinol"},{"key":"2347_CR57","first-page":"3738","volume":"45","author":"X Liu","year":"2017","unstructured":"Liu X, Gao Y, Ye HH, Gerrin S, Ma F, Wu Y, et al. Positive feedback loop mediated by protein phosphatase 1\u03b1 mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res. 2017;45:3738\u201351.","journal-title":"Nucleic Acids Res"},{"key":"2347_CR58","doi-asserted-by":"publisher","first-page":"7125","DOI":"10.1128\/MCB.01753-06","volume":"27","author":"H Zong","year":"2007","unstructured":"Zong H, Chi Y, Wang Y, Yang Y, Zhang L, Chen H, et al. Cyclin D3\/CDK11 p58 complex is involved in the repression of androgen receptor. Mol Cell Biol. 2007;27:7125\u201342.","journal-title":"Mol Cell Biol"},{"key":"2347_CR59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.chembiol.2020.10.001","volume":"28","author":"A Richters","year":"2021","unstructured":"Richters A, Doyle SK, Freeman DB, Lee C, Leifer BS, Jagannathan S, et al. Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors. Cell Chem Biol. 2021;28:134\u201347.","journal-title":"Cell Chem Biol"},{"key":"2347_CR60","doi-asserted-by":"publisher","first-page":"13474","DOI":"10.18632\/oncotarget.24414","volume":"9","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Nakata D, Kakoi Y, Kunitomo M, Murai S, Ebara S, et al. CDK8\/19 inhibition induces premature G1\/S transition and ATRdependent cell death in prostate cancer cells. Oncotarget. 2018;9:13474\u201387.","journal-title":"Oncotarget"},{"key":"2347_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04027-6","volume":"12","author":"H Lei","year":"2021","unstructured":"Lei H, Wang Z, Jiang D, Liu F, Liu M, Lei X, et al. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer. Cell Death Dis. 2021;12:740.","journal-title":"Cell Death Dis"},{"key":"2347_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15:122.","journal-title":"Genome Biol"},{"key":"2347_CR63","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy HHS Public Access. Nat Rev Drug Discov. 2015;14:130\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"2347_CR64","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1158\/0008-5472.CAN-09-0301","volume":"69","author":"S Ali","year":"2009","unstructured":"Ali S, Heathcote DA, Kroll SHB, Jogalekar AS, Scheiper B, Patel H, et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009;69:6208\u201315.","journal-title":"Cancer Res"},{"key":"2347_CR65","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, et al. ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol Cancer Ther. 2018;17:1156\u201366.","journal-title":"Mol Cancer Ther"},{"key":"2347_CR66","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511:616\u201320.","journal-title":"Nature"},{"key":"2347_CR67","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016;12:876\u201384.","journal-title":"Nat Chem Biol"},{"key":"2347_CR68","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.chembiol.2019.02.012","volume":"26","author":"CM Olson","year":"2019","unstructured":"Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, et al. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem Biol. 2019;26:792\u2013803. e10","journal-title":"Cell Chem Biol"},{"key":"2347_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","volume":"37","author":"H Zhang","year":"2020","unstructured":"Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, et al. CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell. 2020;37:37\u201354.","journal-title":"Cancer Cell"},{"key":"2347_CR70","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1021\/acs.jmedchem.1c01171","volume":"65","author":"JJ Marineau","year":"2022","unstructured":"Marineau JJ, Hamman KB, Hu S, Alnemy S, Mihalich J, Kabro A, et al. Discovery of SY-5609: a selective, noncovalent inhibitor of CDK7. J Med Chem. 2022;65:1458\u201380.","journal-title":"J Med Chem"},{"key":"2347_CR71","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-19-0119","volume":"79","author":"S Hu","year":"2019","unstructured":"Hu S, Marineau JJ, Rajagopal N, Hamman KB, Choi YJ, Schmidt DR, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res. 2019;79:3479\u201391.","journal-title":"Cancer Res"},{"key":"2347_CR72","doi-asserted-by":"crossref","unstructured":"Johannessen LH, Hu S, Ke N, D\u2019Ippolito A, Rajagopal N, Marineau J, et al. Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30. AACR: Boston, MA. Philadelphia (PA), 2019, pp C091\u2013C091.","DOI":"10.1158\/1535-7163.TARG-19-C091"},{"key":"2347_CR73","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/S0959-8049(20)31201-6","volume":"138","author":"LK Satyam","year":"2020","unstructured":"Satyam LK, Poddutoori R, Thiyagarajan S, Mukherjee S, Kaza LN, Charamanna K, et al. Potent anti-tumor activity of AUR102, a selective covalent inhibitor of CDK7. Eur J Cancer. 2020;138:S47.","journal-title":"Eur J Cancer"},{"key":"2347_CR74","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/13543784.2013.789859","volume":"22","author":"P Bose","year":"2013","unstructured":"Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs. 2013;22:723\u201338.","journal-title":"Expert Opin Investig Drugs"},{"key":"2347_CR75","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/cmdc.201700447","volume":"12","author":"U L\u00fccking","year":"2017","unstructured":"L\u00fccking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, et al. Identification of Atuveciclib (BAY 1143572), the first highly selective, Clinical PTEFb\/CDK9 inhibitor for the treatment of cancer. ChemMedChem. 2017;12:1776\u201393.","journal-title":"ChemMedChem"},{"key":"2347_CR76","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood-2016-09-741983","volume":"130","author":"T Narita","year":"2017","unstructured":"Narita T, Ishida T, Ito A, Masaki A, Kinoshita S, Suzuki S, et al. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia\/lymphoma. Blood. 2017;130:1114\u201324.","journal-title":"Blood"},{"key":"2347_CR77","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2018-99-117257","volume":"132","author":"M Byrne","year":"2018","unstructured":"Byrne M, Frattini MG, Ottmann OG, Mantzaris I, Wermke M, Lee DJ, et al. Phase I study of the PTEFb inhibitor BAY 1251152 in patients with acute myelogenous leukemia. Blood. 2018;132:4055\u20134055.","journal-title":"Blood"},{"key":"2347_CR78","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1200\/JCO.2018.36.15_suppl.2507","volume":"36","author":"JR Diamond","year":"2018","unstructured":"Diamond JR, Moreno V, Lim EA, Cordoba R, Cai C, Ince SJ, et al. Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity. J Clin Oncol. 2018;36:2507\u20132507.","journal-title":"J Clin Oncol"},{"key":"2347_CR79","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1200\/JCO.2021.39.15_suppl.7538","volume":"39","author":"V Moreno","year":"2021","unstructured":"Moreno V, Cordoba R, Morillo D, Diamond JR, Hamdy AM, Izumi R, et al. Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL). J Clin Oncol. 2021;39:7538\u20137538.","journal-title":"J Clin Oncol"},{"key":"2347_CR80","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, Martin MS, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26:922\u201334.","journal-title":"Clin Cancer Res"},{"key":"2347_CR81","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","volume":"63","author":"B Barlaam","year":"2020","unstructured":"Barlaam B, Casella R, Cidado J, Cook C, De Savi C, Dishington A, et al. Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies. J Med Chem. 2020;63:15564\u201390.","journal-title":"J Med Chem"},{"key":"2347_CR82","doi-asserted-by":"publisher","first-page":"113481","DOI":"10.1016\/j.ejmech.2021.113481","volume":"221","author":"B Jiang","year":"2021","unstructured":"Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, et al. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12\/13 covalent inhibitor with efficacy in Ewing sarcoma. Eur J Med Chem. 2021;221:113481.","journal-title":"Eur J Med Chem"},{"key":"2347_CR83","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, et al. Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer. Cancer Cell. 2019;36:545\u201358. e7","journal-title":"Cancer Cell"},{"key":"2347_CR84","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011\u201325.","journal-title":"Cell"},{"key":"2347_CR85","doi-asserted-by":"publisher","first-page":"e20722","DOI":"10.7554\/eLife.20722","volume":"5","author":"PA Clarke","year":"2016","unstructured":"Clarke PA, Ortiz-Ruiz MJ, Tepoele R, Adeniji-Popoola O, Box G, Court W, et al. Assessing the mechanism and therapeutic potential of modulators of the human mediator complex-associated protein kinases. Elife. 2016;5:e20722.","journal-title":"Elife"},{"key":"2347_CR86","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/cells8111413","volume":"8","author":"M Chen","year":"2019","unstructured":"Chen M, Li J, Liang J, Thompson ZS, Kathrein K, Broude EV, et al. Systemic toxicity reported for CDK8\/19 inhibitors CCT251921 and MSC2530818 is not due to target inhibition. Cells. 2019;8:1413.","journal-title":"Cells"},{"key":"2347_CR87","doi-asserted-by":"publisher","first-page":"33779","DOI":"10.18632\/oncotarget.16810","volume":"8","author":"T Rzymski","year":"2017","unstructured":"Rzymski T, Mikula M, Zylkiewicz E, Dreas A, Wiklik K, Golas A, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget. 2017;8:33779\u201395.","journal-title":"Oncotarget"},{"key":"2347_CR88","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.celrep.2017.09.056","volume":"21","author":"S Kalan","year":"2017","unstructured":"Kalan S, Amat R, Schachter MM, Kwiatkowski N, Abraham BJ, Liang Y, et al. Activation of the p53 transcriptional program sensitizes cancer cells to Cdk7 inhibitors. Cell Rep. 2017;21:467\u201381.","journal-title":"Cell Rep"},{"key":"2347_CR89","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.1016\/j.annonc.2021.08.291","volume":"32","author":"SH Henry","year":"2021","unstructured":"Henry SH, Johannessen L, Sawant P, Lefkovith A, Ke N, Dworakowski W, et al. 13P SY-5609, a highly potent and selective oral CDK7 inhibitor, exhibits robust antitumor activity in preclinical models of KRAS mutant cancers as a single agent and in combination with chemotherapy. Ann Oncol. 2021;32:S364\u2013S375.","journal-title":"Ann Oncol"},{"key":"2347_CR90","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.cell.2018.09.051","volume":"175","author":"H Zhang","year":"2018","unstructured":"Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, et al. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell. 2018;175:1244\u20131258. e26","journal-title":"Cell"},{"key":"2347_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01301-7","volume":"20","author":"Y Wei","year":"2021","unstructured":"Wei Y, Li C, Bian H, Qian W, Jin K, Xu T, et al. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Mol Cancer. 2021;20:5.","journal-title":"Mol Cancer"},{"key":"2347_CR92","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/cells9030638","volume":"9","author":"MSJ McDermott","year":"2020","unstructured":"McDermott MSJ, Sharko AC, Munie J, Kassler S, Melendez T, Lim CU, et al. CDK7 inhibition is effective in all the subtypes of breast cancer: determinants of response and synergy with EGFR inhibition. Cells. 2020;9:638.","journal-title":"Cells"},{"key":"2347_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1161-9","volume":"21","author":"RP McLaughlin","year":"2019","unstructured":"McLaughlin RP, He J, Van Der Noord VE, Redel J, Foekens JA, Martens JWM, et al. A kinase inhibitor screen identifies a dual cdc7\/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. Breast Cancer Res. 2019;21:77.","journal-title":"Breast Cancer Res"},{"key":"2347_CR94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/2159-8290.CD-17-0461","volume":"8","author":"M Rusan","year":"2018","unstructured":"Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, et al. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discov. 2018;8:59\u201373.","journal-title":"Cancer Discov"},{"key":"2347_CR95","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41388-019-0953-9","volume":"39","author":"B Sun","year":"2020","unstructured":"Sun B, Mason S, Wilson RC, Hazard SE, Wang Y, Fang R, et al. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene. 2020;39:50\u201363.","journal-title":"Oncogene"},{"key":"2347_CR96","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41375-019-0652-0","volume":"34","author":"DC Phillips","year":"2020","unstructured":"Phillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, et al. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2020;34:1646\u201357.","journal-title":"Leukemia"},{"key":"2347_CR97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","volume":"5","author":"DA Luedtke","year":"2020","unstructured":"Luedtke DA, Su Y, Ma J, Li X, Buck SA, Edwards H, et al. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduct Target Ther. 2020;5:17.","journal-title":"Signal Transduct Target Ther"},{"key":"2347_CR98","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-0078","volume":"16","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Peng H, Wang X, Yin X, Ma P, Jing Y, et al. Preclinical efficacy and molecular mechanism of targeting CDK7-dependent transcriptional addiction in ovarian cancer. Mol Cancer Ther. 2017;16:1739\u201350.","journal-title":"Mol Cancer Ther"},{"key":"2347_CR99","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41588-018-0191-z","volume":"50","author":"AD Durbin","year":"2018","unstructured":"Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet 2018;50:1240\u20136.","journal-title":"Nat Genet"},{"key":"2347_CR100","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/bloodadvances.2019000586","volume":"4","author":"H McCalmont","year":"2020","unstructured":"McCalmont H, Li KL, Jones L, Toubia J, Bray SC, Casolari DA, et al. Efficacy of combined CDK9\/BET inhibition in preclinical models of MLL-rearranged acute leukemia. Blood Adv. 2020;4:296\u2013300.","journal-title":"Blood Adv"},{"key":"2347_CR101","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","volume":"31","author":"S Nagaraja","year":"2017","unstructured":"Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell. 2017;31:635\u201352.","journal-title":"Cancer Cell"},{"key":"2347_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-00137-0","volume":"4","author":"X Chen","year":"2020","unstructured":"Chen X, Ma Q, Shang Z, Niu Y. Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets. npj Precis Oncol. 2020;4:31.","journal-title":"npj Precis Oncol"},{"key":"2347_CR103","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","volume":"175","author":"W Minzel","year":"2018","unstructured":"Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, et al. Small molecules co-targeting CKI\u03b1 and the transcriptional Kinases CDK7\/9 Control AML in preclinical models. Cell. 2018;175:171\u2013185. e25.","journal-title":"Cell"},{"key":"2347_CR104","doi-asserted-by":"crossref","unstructured":"Guarducci C, Nardone A, Feiglin A, Migliaccio I, Malorni L, Bonechi M, et al. Abstract PD7-12: Inhibition of CDK7 overcomes resistance to CDK4\/6 inhibitors in hormone receptor positive breast cancer cells. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8. AACR: San Antonio, TX. Philadelphia (PA), 2019, pp PD7\u221212.","DOI":"10.1158\/1538-7445.SABCS18-PD7-12"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02347-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T06:05:32Z","timestamp":1654841132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02347-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":104,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,6,10]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1038\/s41388-022-02347-1","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CLB has received research grant funding from Carrick Therapeutics. Other authors declare no potential competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}